Rapid Micro Biosystems stock gained 6.13 percent on October 5

Published on 10/06/2026 at 10:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rapid Micro Biosystems stock traded at USD 0.98 on October 5, with market value at USD 44.3 million. Q2 revenue reached USD 8.1 million, up 11 percent year over year.

RPID, US75340L1044, Illustration mit AI erstellt.

Rapid Micro Biosystems (US75340L1044) stock was last at USD 0.98 on Nasdaq on October 5, 2026 at 4:00 p.m. ET, up 6.13 percent on the session. The latest operating figures and fresh analyst coverage give the small-cap life sciences company two separate valuation reference points.

Revenue growth sets the frame

Rapid Micro Biosystems reported USD 8.1 million in total revenue for Q2 2026, up 11 percent from Q2 2025, according to Rapid Micro Biosystems. The company also said it placed four Growth Direct systems and completed nine validations during the quarter.

The company reached 200 Growth Direct systems placed globally in Q2 2026, a milestone that matters because the platform combines equipment with recurring consumables and service revenue. The installed base gives the business a larger foundation for repeat sales than a one-time equipment model.

Analyst targets widen the valuation gap

Roth/MKM initiated coverage on September 29, 2026, with a Buy rating and a USD 3.00 price target, as Investing.com reported. Against the October 5 price of USD 0.98, that target lies 206.1 percent above the price.

The published consensus was Strong Buy from 3 analysts, with an average 12-month target of USD 6.6667, a high of USD 8.00 and a low of USD 5.00, according to Investing.com. The average target lies 578.2 percent above the Nasdaq price, while the wide spread between USD 3.00 and USD 8.00 shows how heavily valuation depends on execution.

Stock gained on October 5

Rapid Micro Biosystems stock was last at USD 0.98 on Nasdaq on October 5, 2026, with a session range of USD 0.91 to USD 1.15. Trading volume reached 444,740 shares, and the market capitalization was USD 44.3 million.

The shares remain close to the lower end of the USD 0.86 to USD 4.94 52-week range. For investors, the central test is whether quarterly revenue growth and the expanding Growth Direct installed base can narrow the gap between the operating business and the much higher analyst targets.